<DOC>
	<DOCNO>NCT02277639</DOCNO>
	<brief_summary>This Phase II trial determine ability reduce intensity condition regimen allow successful engraftment CD3+ /CD19+ deplete peripheral stem cell graft mismatch donor . There two conditioning regimen depend upon patient diagnosis age .</brief_summary>
	<brief_title>Reduced Intensity Conditioning Using CD3+/CD19+ Depletion Non Malignant Transplantable Diseases</brief_title>
	<detailed_description>This study allow transplantation use reduce intensity condition regimen child non-malignant disease lack match related unrelated donor . Donors unrelated partially match relate , depend upon urgency availability . If parent haploidentical , mother preferred , evidence reduce transplant related mortality superior survival maternal donor . The risk severe graft v host disease ( GVHD ) Epstein-Barr lymphoproliferative disorder reduce eliminate T B cell depletion use Miltenyi Clinimacs device . Patients bone marrow failure syndrome , high risk rejection , undergo pre-conditioning immune suppression Thymoglobulin . It recommend patient immunedysregulation syndrome receive pre-RIC alemtuzumab may reduce risk non-engraftment hyperinflammatory state . Post-transplant immune suppression use prevent GVHD , CD3 depletion deplete completely CD34+ selection . It rapidly wean GVHD day 100 allow immune reconstitution .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Pancytopenia</mesh_term>
	<mesh_term>Hemoglobinuria , Paroxysmal</mesh_term>
	<criteria>Bone marrow failure syndromes SCT indicate , include severe aplastic anemia refractory non transplant therapy congenital neutropenia , congenital thrombocytopenia , congenital red cell aplasia Immunodeficiencies allogeneic hematopoietic stem cell transplant indicate , include severe combine immunodeficiency , WiskottAldrich syndrome , IPEX syndrome , Xlinked lymphoproliferative disease Immune dysregulation syndrome , include refractory recurrent hemophagocytic lymphohistiocytosis , HLH genetic mutation , refractory multisystemic Langerhans cell histiocytosis , MAS refractory standard therapy Organ function clearance Uncontrolled bacterial , viral fungal infection HLA match related unrelated donor able donate mobilize peripheral stem cell . Fanconi 's syndrome , dyskeratosis congenita chromosomal fragility syndrome Pregnant Females</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>22 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Transplant related mortality</keyword>
	<keyword>Graft versus host disease</keyword>
	<keyword>Bone marrow transplant</keyword>
</DOC>